Trials / Completed
CompletedNCT00489905
Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Hospital Authority, Hong Kong · Other Government
- Sex
- Male
- Age
- 50 Years – 80 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zolderonic acid (Zometa) |
Timeline
- Start date
- 2005-04-01
- Completion
- 2008-05-01
- First posted
- 2007-06-21
- Last updated
- 2013-10-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00489905. Inclusion in this directory is not an endorsement.